ClinConnect ClinConnect Logo
Search / Trial NCT04559373

Virtual Reality and Field Training to Enhance Community Walking After Stroke

Launched by MCGILL UNIVERSITY · Sep 16, 2020

Trial Information

Current as of August 21, 2025

Recruiting

Keywords

Aging Biomechanics Community Ambulation Intervention Locomotion Rehabilitation Sensorimotor Integration Virtual Reality

ClinConnect Summary

This clinical trial is studying a new way to help stroke survivors walk better in their communities after they finish rehabilitation. The researchers are testing a program that combines virtual reality (VR) training with real-world practice. Participants will use VR goggles to navigate a simulated shopping mall and streets, which will help them improve their walking skills in a fun and engaging way. The program lasts four weeks, with three VR training sessions each week and two sessions of practicing walking in the community with family or caregivers. The goal is to see how well this program works and how safe and enjoyable it is for participants.

To be eligible for this trial, participants should be between 40 and 74 years old and have had a stroke that affects their walking abilities but still allows them to walk independently for at least one minute. They should also have some cognitive and visual abilities intact. The researchers want to ensure that everyone feels comfortable and safe during the training, so they will monitor how well participants adhere to the program and assess their overall safety. This study aims to provide valuable information on how different individuals respond to this innovative walking program.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • People with chronic stroke and persistent deficits in walking / visual-perceptual / cognitive capacities. They can be male or female, aged from 40 to 74 years, with normal/corrected visual and auditory acuity, and present with:
  • First-ever supratentorial unilateral stroke 9-24 months ago (such chronicity will ensure steady-state mobility without long-term disuse-related changes
  • Mild-to-moderate hemiparesis (Chedoke McMaster Stoke Assessment stages 4/7-6/7 on postural control, leg \& foot)
  • Ability to walk independently with/without walking aids for at least 1 min at 0.4-0.9 m/s (such a speed range indicates mobility not sufficient for functional community ambulation: shopping \~1.1m/s, street crossing \~1.2 m/s)
  • Intact or mildly affected cognitive function (Montreal Cognitive Assessment scores ≥ 22/30)
  • Intact to moderately affected visual-perceptual function (positive scores on a maximum of 3/6 tasks on the Behavioural Inattention Test)
  • Exclusion Criteria:
  • Subjects with comorbidities interfering with walking
  • Subjects with comorbidities interfering with visual perception
  • Subjects without medical clearance for exercise

About Mcgill University

McGill University, a prestigious research institution located in Montreal, Canada, is committed to advancing medical science through innovative clinical trials. Renowned for its rigorous academic standards and collaborative approach, McGill fosters a dynamic environment that integrates cutting-edge research with clinical practice. With a focus on improving patient outcomes, the university's clinical trials span a wide range of therapeutic areas, leveraging the expertise of its diverse faculty and state-of-the-art facilities. McGill University is dedicated to ethical research practices and the dissemination of knowledge, ensuring that findings contribute meaningfully to the global healthcare landscape.

Locations

Laval, Quebec, Canada

Québec, , Canada

Québec, Quebec, Canada

Patients applied

0 patients applied

Trial Officials

Anouk Lamontagne, PhD

Principal Investigator

McGill University

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials